Suchen
Sarepta Therapeutics Inc
SRPTZur Watchlist hinzufügen
17.550USD
-1.130-6.05%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
1.97BMarktkapitalisierung
28.16KGV TTM
mehr Informationen über Sarepta Therapeutics Inc Unternehmen
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Sarepta Therapeutics Inc Informationen
BörsenkürzelSRPT
Name des UnternehmensSarepta Therapeutics Inc
IPO-datumJun 04, 1997
CEOIngram (Douglas S)
Anzahl der mitarbeiter1372
WertpapierartOrdinary Share
GeschäftsjahresendeJun 04
Addresse215 First Street
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142
Telefon16172744000
Websitehttps://www.sarepta.com/
BörsenkürzelSRPT
IPO-datumJun 04, 1997
CEOIngram (Douglas S)
Führungskräfte von Sarepta Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.22M
+0.07%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
54.56K
-263.23%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
31.53K
+7.56%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
31.22K
-492.36%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
25.22K
+9.45%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
11.52K
-1072.63%
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Dr. Stephen L. Mayo, Ph.D.
Dr. Stephen L. Mayo, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.22M
+0.07%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
54.56K
-263.23%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
31.53K
+7.56%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
31.22K
-492.36%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PMO Products
965.57M
43.92%
ELEVIDYS
898.73M
40.88%
collaboration and other
333.94M
15.19%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.70B
77.29%
Rest of World
165.18M
7.51%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PMO Products
965.57M
43.92%
ELEVIDYS
898.73M
40.88%
collaboration and other
333.94M
15.19%
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.89%
AQR Capital Management, LLC
7.38%
Vanguard Portfolio Management, LLC
6.29%
State Street Investment Management (US)
6.25%
Vanguard Capital Management, LLC
4.34%
Andere
63.85%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.89%
AQR Capital Management, LLC
7.38%
Vanguard Portfolio Management, LLC
6.29%
State Street Investment Management (US)
6.25%
Vanguard Capital Management, LLC
4.34%
Andere
63.85%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
41.23%
Investment Advisor/Hedge Fund
28.79%
Hedge Fund
11.54%
Research Firm
6.41%
Individual Investor
4.09%
Pension Fund
1.88%
Bank and Trust
0.73%
Family Office
0.45%
Sovereign Wealth Fund
0.35%
Andere
4.54%
Institutionelle Beteiligung
Aktualisiert: Sun, Apr 5
Aktualisiert: Sun, Apr 5
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
1037
95.57M
90.53%
-25.27M
2025Q4
1032
91.00M
86.84%
-18.75M
2025Q3
1019
84.30M
80.53%
-21.85M
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
12.56M
11.96%
+1.03M
+8.96%
Dec 31, 2025
AQR Capital Management, LLC
7.80M
7.43%
+6.39M
+454.65%
Dec 31, 2025
State Street Investment Management (US)
6.60M
6.29%
+1.29M
+24.40%
Dec 31, 2025
Two Sigma Investments, LP
4.51M
4.3%
+416.99K
+10.18%
Dec 31, 2025
Barry (Richard J)
3.21M
3.06%
+32.60K
+1.02%
May 16, 2025
Erste Asset Management GmbH
2.73M
2.6%
+43.00K
+1.60%
Dec 31, 2025
abrdn Inc.
2.25M
2.14%
+268.83K
+13.56%
Dec 31, 2025
UBS Financial Services, Inc.
2.06M
1.96%
+82.28K
+4.16%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Neuroscience and Healthcare ETF
3.74%
First Trust NYSE Arca Biotechnology Index Fund
3.65%
Invesco Biotechnology & Genome ETF
3.49%
Invesco S&P SmallCap Health Care ETF
1.44%
Global X Genomics & Biotechnology ETF
1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
1.32%
Virtus LifeSci Biotech Products ETF
1.03%
State Street SPDR S&P Biotech ETF
1.03%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Health Care Alphadex Fund
0.51%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil3.74%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.65%
Invesco Biotechnology & Genome ETF
Anteil3.49%
Invesco S&P SmallCap Health Care ETF
Anteil1.44%
Global X Genomics & Biotechnology ETF
Anteil1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
Anteil1.32%
Virtus LifeSci Biotech Products ETF
Anteil1.03%
State Street SPDR S&P Biotech ETF
Anteil1.03%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.63%
First Trust Health Care Alphadex Fund
Anteil0.51%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
